A closer look at amphetamine-induced reverse transport and trafficking of the dopamine and norepinephrine transporters.

A closer look at amphetamine-induced reverse transport and trafficking of the dopamine and norepinephrine transporters.
复制标题

DOI:
10.1007/s12035-009-8053-4
复制
发表时间:
2009-04
影响因子:
5.1
通讯作者:
Galli A
Galli A
中科院分区:
医学2区
文献类型:
--
作者:
Robertson SD;Matthies HJ;Galli A

文献摘要

参考文献

被引文献

相似文献

安非他明(AMPH)及其衍生物经常用于治疗多种疾病,例如注意力缺陷多动障碍(ADHD)、肥胖、创伤性脑损伤和嗜睡症。尽管AMPH具有重要的药用作用,但它作为滥用药物的精神兴奋剂和成瘾特性更为广泛地了解。AMPH的主要分子靶点是囊泡单胺转运体(VMATs)和质膜单胺-多巴胺(DA)、去甲肾上腺素(NE)和5-羟色胺(5-HT)-转运体。AMPH的奖赏和成瘾特性依赖于其作为这些转运蛋白的底物并最终增加细胞外单胺水平的能力。AMPH通过诱导突触囊泡耗竭(这增加了细胞内单胺水平)以及通过促进质膜单胺转运蛋白的反向转运(流出)来实现神经递质细胞外水平的升高。本文将重点介绍AMPH诱导的质膜单胺转运蛋白调节的两个重要方面--转运蛋白介导的单胺外排和转运蛋白运输。
Amphetamine (AMPH) and its derivatives are regularly used in the treatment of a wide array of disorders such as attention deficit hyperactivity disorder (ADHD), obesity, traumatic brain injury, and narcolepsy. Despite the important medicinal role for AMPH, it is more widely known for its psychostimulant and addictive properties as a drug of abuse. The primary molecular targets of AMPH are both the vesicular monoamine transporters (VMATs) and plasma membrane monoamine—dopamine (DA), norepinephrine (NE), and serotonin (5-HT)—transporters. The rewarding and addicting properties of AMPH rely on its ability to act as a substrate for these transporters and ultimately increase extracellular levels of monoamines. AMPH achieves this elevation in extracellular levels of neurotransmitter by inducing synaptic vesicle depletion, which increases intracellular monoamine levels, and also by promoting reverse transport (efflux) through plasma membrane monoamine transporters. This review will focus on two important aspects of AMPH-induced regulation of the plasma membrane monoamine transporters—transporter mediated monoamine efflux and transporter trafficking.
DOI: 10.1073/pnas.0804659105
发表时间: 2008-07-29
影响因子: 11.1
作者:
Forrest, Lucy R.;Zhang, Yuan-Wei;Rudnick, Gary
通讯作者: Rudnick, Gary
DOI: 10.1074/jbc.m501969200
发表时间: 2005-12-09
影响因子: 4.8
作者:
Cervinski, MA;Foster, JD;Vaughan, RA
通讯作者: Vaughan, RA
DOI: 10.1016/s0896-6273(00)80418-3
发表时间: 1997-12-01
期刊: NEURON
影响因子: 16.2
作者:
Fon, EA;Pothos, EN;Edwards, RH
通讯作者: Edwards, RH
DOI: 10.1016/j.neuropharm.2007.11.007
发表时间: 2008-03-01
期刊: NEUROPHARMACOLOGY
影响因子: 4.7
作者:
Boudanova, Ekaterina;Navaroli, Deanna A.;Melikian, Haley E.
通讯作者: Melikian, Haley E.
DOI: 10.1074/jbc.273.20.12675
发表时间: 1998-05-15
影响因子: 4.8
作者:
Chen, JG;Liu-Chen, S;Rudnick, G
通讯作者: Rudnick, G